STEP Young Trial: Wegovy Results in Kids Aged 6 to 11

The short answer

STEP Young was Novo Nordisk's phase 3 trial of weekly semaglutide (the drug in Wegovy) in children aged 6 to under 12 with obesity. Full results, published in the New England Journal of Medicine on November 16, 2026, showed BMI fell 13.5% at 68 weeks versus a 2.7% rise on placebo, and about 4 in 10 children no longer had obesity. Stomach side effects were most common, and no growth or puberty concerns were found, but Wegovy is still not approved under age 12. Parents on a GLP-1 themselves can keep their own protein and workouts steady with Sharpy.

What did the STEP Young trial find? In children aged 6 to under 12 with obesity, weekly semaglutide (the drug in Wegovy) lowered BMI by 13.5% after 68 weeks, while BMI rose 2.7% in children on placebo. The full results were published in the New England Journal of Medicine on November 16, 2026, and presented at ObesityWeek in Washington, DC. Stomach upset was the most common side effect. No growth or puberty concerns were reported. Wegovy is still not approved for children under 12 in the US.

This guide reads the trial in plain English for parents. It is not advice for any one child. Whether a young child should ever take a GLP-1 is a decision for a pediatrician or pediatric obesity specialist.

What is the STEP Young clinical trial?

STEP Young (ClinicalTrials.gov NCT05726227) is a phase 3 trial sponsored by Novo Nordisk. Here is how it was set up:

Detail STEP Young
Who Children aged 6 to under 12 with obesity (BMI at or above the 95th percentile for age and sex)
How many 165 children, per Novo Nordisk, randomized 2 to 1 to semaglutide or placebo
Design Randomized, double-blind, placebo-controlled, multinational
Drug Semaglutide injection once a week
Top dose 1.7 mg (children 45 to 60 kg) or 2.4 mg (over 60 kg)
Extra support Healthier eating and more physical activity for every child
Main time point 68 weeks, with treatment continuing to 104 weeks, then 7 weeks off drug
Published NEJM, November 16, 2026 (Jastreboff and colleagues)

Novo Nordisk said more than 85% of the children started with severe (class II or III) obesity. That matters. These were not children with a few extra pounds. Most had a high level of obesity that often brings other health problems.

STEP Young results: the numbers

Two analyses were published, and news stories have mixed them up. The "treatment-regimen" analysis counts every child, including those who missed doses or stopped. It is the main analysis and the more realistic one. The "efficacy" analysis estimates what would happen if every child took the drug as planned.

Result at 68 weeks Semaglutide Placebo
BMI change, main analysis -13.5% +2.7%
BMI change, if all took the drug as planned -17.4% +2.2%
Moved to a lower BMI category, main analysis 78.8% 23.4%
No longer had obesity, main analysis 38.4% 2.1%
No longer had obesity, if all took the drug as planned 40.4% 0%
BMI down by at least 10%, main analysis 74.7% 4.3%

So the "40% of kids no longer obese" headline from September is real, but it is the best-case analysis. The everyday-use number is a bit lower at 38.4%.

Why BMI and not pounds? Children are still growing. A child can gain height and some weight and still become healthier. That is why the placebo group's BMI went up: growing kids with obesity often keep moving further above the healthy range without treatment.

What happened by week 104?

Treatment continued to two years. The effect held, but it was smaller than at 68 weeks:

Result at 104 weeks Semaglutide Placebo
BMI change, main analysis -9.4% +8.4%
BMI change, if all took the drug as planned -14.0% +5.7%

These later results were secondary and were not adjusted for multiple comparisons, so read them as supportive, not final. The trial also followed children for 7 weeks after the drug stopped. What happens to weight once a young child stops semaglutide long term is not yet known.

Is semaglutide safe for children? Side effects in STEP Young

Here is what the published reports say about safety:

  • Any side effect: 96% of children on semaglutide and 93% on placebo reported at least one adverse event. Colds, fevers and stomach bugs are common in this age group, which is why the placebo number is high too.
  • Stomach problems: nausea, vomiting and similar effects were the most common and happened more often with semaglutide.
  • Stopping the drug: one child on semaglutide stopped because of stomach side effects.
  • Growth and puberty: Novo Nordisk said no safety concerns were found for growth or pubertal development.
  • Overall: the safety picture matched earlier semaglutide and liraglutide trials, with no new safety signals reported.

The Wegovy label also carries a boxed warning about thyroid C-cell tumors, and in November 2026 the FDA asked for a new warning about a rare optic nerve problem (NAION) on all GLP-1 labels. Our FDA GLP-1 eye warning guide explains it. Long-term effects on bones, growth and eating habits in young children still need study.

STEP Young vs other GLP-1 trials in kids and teens

Trial Drug Age Length BMI change vs placebo
SCALE Kids (NEJM, 2024) Liraglutide, daily 6 to 11 56 weeks -5.8% vs +1.6%
STEP Young (NEJM, 2026) Semaglutide, weekly 6 to under 12 68 weeks -13.5% vs +2.7%
STEP TEENS (Wegovy label) Semaglutide, weekly 12 to 17 68 weeks -16.1% vs +0.6%

Semaglutide lowered BMI more than liraglutide did in young children, though these were separate trials, not a head-to-head test. For teens, see our guide to GLP-1 for teens. For the full picture of what is approved under 12, including the EU's Saxenda decision, see GLP-1 for kids under 12.

Is Wegovy approved for kids under 12 now?

No. Wegovy injection is FDA approved for chronic weight management in adults and in children aged 12 and older. The Wegovy pill is approved for adults only. Novo Nordisk says STEP Young was run to meet regulators' post-marketing requirements, but it has not announced when, or whether, it will ask the FDA or EMA to lower the age. A doctor who prescribes semaglutide to a child under 12 today is doing so off label.

Please avoid compounded or "research grade" semaglutide sold online for children. These products are not FDA approved, and dosing errors with compounded semaglutide have sent people to the hospital. Our guide to compounded GLP-1 risks explains why.

Questions for your child's doctor

  • Does my child meet any approved label, now or if the label changes?
  • What did STEP Young show for children like mine in age and BMI?
  • How will growth, puberty, vitamin D and iron be checked?
  • Who sets protein and calorie targets for a growing body?
  • What is the plan if my child stops the medicine?
  • Are there any signs of disordered eating? See GLP-1 drugs and eating disorders.

What this means for families

Every child in STEP Young also got help with food and activity. The drug worked on top of those habits, not instead of them. Protein at each meal, active play most days and regular meal times help the whole household, whether or not anyone takes a GLP-1.

Many parents reading about this trial are on a GLP-1 themselves. If that is you, Sharpy gives you one daily protein target, one 20-minute workout and a Shape Score, so you protect your own muscle while you model good habits at home. Sharpy is for adults and does not give medical advice.

The bottom line

The STEP Young trial is the strongest evidence yet that semaglutide can lower BMI in children aged 6 to 11 with obesity: 13.5% in the main analysis, with about 4 in 10 children no longer in the obesity range. Side effects were mostly stomach related, and no growth or puberty concerns were reported. It is not an approval, and long-term data are still missing, so any decision belongs with a pediatric specialist. For adults on a GLP-1, Sharpy keeps protein, a short workout and progress in one daily check-in.

Sources

Questions people ask

What is the STEP Young trial?

STEP Young (NCT05726227) is a phase 3, randomized, double-blind, placebo-controlled trial run by Novo Nordisk. It tested once-weekly semaglutide injections plus a healthy eating and activity program in children aged 6 to under 12 with obesity. The main result was measured at 68 weeks, and treatment continued to 104 weeks.

What were the STEP Young results?

In the main analysis, which counts every child whether or not they kept taking the drug, BMI fell 13.5% on semaglutide and rose 2.7% on placebo at 68 weeks. If every child had stayed on treatment, the estimate was a 17.4% drop versus a 2.2% rise. Results were published in NEJM on November 16, 2026.

Is semaglutide approved for children under 12?

No. In the US, Wegovy injection is approved for chronic weight management from age 12. STEP Young is a trial result, not an approval. Novo Nordisk has not announced a date for asking the FDA to extend the label to younger children.

Is semaglutide safe for children?

In STEP Young, stomach problems such as nausea and vomiting were the most common side effects, and they were more frequent than on placebo. One child stopped the drug because of stomach side effects. Novo Nordisk said no safety concerns were found for growth or puberty. Long-term effects in young children are still unknown.

What dose of semaglutide was used in STEP Young?

Children got a once-weekly injection that was raised step by step to a maximum of 1.7 mg or 2.4 mg, depending on body weight at the start. Children weighing 45 to 60 kg could reach 1.7 mg, and those over 60 kg could reach 2.4 mg. This is a trial protocol, not dosing advice for any child.

Why do the STEP Young numbers differ between articles?

Two analyses were reported. The 13.5% BMI drop is the main analysis, which includes children who stopped or missed doses. The 17.4% drop estimates what happens if every child takes the drug as planned. Both are measured at 68 weeks. The 40.4% "no longer obese" figure comes from the second analysis.

Read next